Pembrolizumab (+) Berahyaluronidase alfa(Merck)은 Metastatic Non-small Cell Lung Cancer 표적 항체로, Advanced or Metastatic Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 64.3% (ClinicalTrials.gov NCT06212752). PK: t½ 3 h. 차별점: novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo.
Metastatic Non-small Cell Lung Cancer
Advanced or Metastatic Solid Tumors
Active
vedotin after avelumab
humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3)
novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo
checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev
T cell activation
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
biomarker-driven immunotherapy
escape driven by multiple mechanisms
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Pembrolizumab (+) Berahyaluronidase alfa(Merck)은 Metastatic Non-small Cell Lung Cancer 표적 항체로, Advanced or Metastatic Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 64.3% (ClinicalTrials.gov NCT06212752). PK: t½ 3 h. 차별점: novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo.
Metastatic Non-small Cell Lung Cancer
Advanced or Metastatic Solid Tumors
Active
vedotin after avelumab
humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3)
novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumo
checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev
T cell activation
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
biomarker-driven immunotherapy
escape driven by multiple mechanisms
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.